期刊文献+

高效液相色谱荧光检测法测定人血浆中9-氨基喜树碱的浓度 被引量:2

HPLC determination of 9-aminocamptothecin in human plasma with fluorescence detector
原文传递
导出
摘要 目的:建立测定人血浆中9-氨基喜树碱浓度的高效液相色谱-荧光检测法。方法;以喜树碱为内标,以C18固相萃取小柱处理血浆样品,采用荧光检测器检测。色谱柱为KromasilC18色谱分析柱(250mm×4.6mm,5μm),甲醇-磷酸盐缓冲液(48∶52,pH=2.5)为流动相,流速为1.0mL.min-1,柱温30℃,荧光检测器激发波长366nm,发射波长456nm,进样量50μL。结果:9-氨基喜树碱血浆浓度线性范围为0.5~100ng·mL-1(r=0.9998),最低定量限为0.5ng·mL-1,方法回收率为96.8%~102.5%,日内精密度RSD为5.8%~7.3%,日间精密度RSD为1.3%~6.6%。结论:该方法操作简便、专属性强且灵敏度高,适用于血浆9-氨基喜树碱浓度测定和人体药动学研究。 Objective:To establish an HPLC method with fluorescence detection for the quantitation of 9-aminocamptothecin in human plasma.Methods:Camptothecin was adopted as the internal standard.9-aminocamptothecin was extracted from plasma using solid phase extraction (SPE).The Kromasil C18 column (250 mm×4.6 mm,5 μm) was adopted as analytical column.The mobile phase consisted of methanol and phosphate buffer solution (48:52,pH=2.5).The flow rate was 1.0 mL·min-1,and the column temperature was at 30 ℃.Excitation wavelength and emission wavelength of fluorescence detection were set at 366 nm and 456 nm,respectively.The injection volume was 50 μL.Results:A good linear relationship was obtained in the concentration range of 0.5 to 100 ng·mL-1.The limit of quantitative concentration was 0.5 ng·mL-1.The relative recovery was between 96.8% and 102.5%.The intra-day precision was between 5.8% and 7.3% and The inter-day precision was between 1.3% and 6.6%.Conclusions:The presented method is simple,accurate and sensitive.It was successfully applied to the determination of 9-aminocamptothecin in human plasma and clinical pharmacokinetic study.
出处 《药物分析杂志》 CAS CSCD 北大核心 2010年第8期1416-1419,共4页 Chinese Journal of Pharmaceutical Analysis
关键词 9-氨基喜树碱 9-硝基喜树碱 高效液相色谱 荧光检测器 固相萃取 9-aminocamptothecin 9-nitrocamptothecin HPLC fluorescence detector solid phase extraction
  • 相关文献

参考文献8

  • 1Natelson EA,Giovanella BC,Verschraegen CF,et al.Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents.Ann N Y Acad Sci,1996,803:224.
  • 2Hinz HR,Harris NJ,Natelson EA,et al.Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans,dogs,and mice.Cancer Res,1994,54 (12):3096.
  • 3Takimoto CH,Thomas R.The clinical development of 9-aminocamptothecin.Ann N Y Acad Sci,2000,922:224.
  • 4阎昭,王华庆,张荣荣,张洁,郝希山.高效液相色谱法测定人血浆中9-硝基喜树碱的含量[J].中国医院药学杂志,2006,26(4):378-380. 被引量:4
  • 5Schoemaker NE,Rosing H,Jansen S,et al.Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection.J Chromatogr B Analyt Technol Biomed Life Sci,2002,775 (2):231.
  • 6Pantazis P,Harris N,Mendoza J,et al.The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human hematopoietic and other cells.Eur J Haematol,1995,55 (3):211.
  • 7Zhang,J,Burke TG,Latus LJ.Determination of 9-nitrocamptothecin by precolumn derivatization and its metabolite 9-aminocamptothecin in a biological fluid using reversed-phase high-performance liquid chromatography with fluorescence detection.J Chromatogr B Analyt Technol Biomed Life Sci,2003,795 (2):309.
  • 8Zamboni WC,Goel S,Iqbal T,et al.Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.Cancer Chemother Pharmacol,2006,57 (5):631.

二级参考文献7

  • 1Zamboni WC,Jung LL,Egorin MJ,et al.Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts[J].Clin Cancer Res,2005,11(13):4867-74.
  • 2Virginine M M Herben,Roel van Gijin,Jan H M,et al.Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-amino-camptothecin in a colloidaldispersion formulation in patients with advanced solid tumors[J].Journal of Clinical Oncology,1999,17:1906.
  • 3Verschraegen CF,Natelson EA,Giovanella BC,et al.A Phase I and pharmacokinetic study of oral 9-nitro-camptothecin,a novel water-insoluble topoisomerase I inhibitor[J].Anti Cancer Drugs,1998,9(1):36-44.
  • 4Nadja E,Schoemaker,Jan H M,et al.Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule[J].Cancer Chemother Pharmacol,2002,50:514-517.
  • 5Nadja E,Schoemaker,Hilde Rosing,et al.Determination of 9-nitro-camptothecin and its metabolite 9-amino-camptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection[J].Journal of Chromatography B,2002,775:231-237.
  • 6陈勇川,臧雷,穆海川.固相萃取高效液相色谱法测定人血浆中伊贝沙坦浓度[J].药物分析杂志,2001,21(3):196-197. 被引量:4
  • 7李柯,钟大放.高效液相色谱法测定大鼠组织及血浆中9-硝基喜树碱含量[J].药学学报,2003,38(2):124-128. 被引量:18

共引文献3

同被引文献14

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部